Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) President Cam Gallagher Sells 1,173 Shares

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTLGet Free Report) President Cam Gallagher sold 1,173 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $11.44, for a total value of $13,419.12. Following the transaction, the president now directly owns 643,277 shares in the company, valued at $7,359,088.88. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL stock opened at $11.50 on Tuesday. The firm has a 50-day moving average of $13.65 and a 200-day moving average of $17.62. Zentalis Pharmaceuticals, Inc. has a one year low of $9.56 and a one year high of $31.46.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. US Bancorp DE boosted its stake in shares of Zentalis Pharmaceuticals by 88.7% in the 2nd quarter. US Bancorp DE now owns 887 shares of the company’s stock worth $25,000 after buying an additional 417 shares during the last quarter. Captrust Financial Advisors increased its position in shares of Zentalis Pharmaceuticals by 15,160.0% during the first quarter. Captrust Financial Advisors now owns 763 shares of the company’s stock valued at $35,000 after acquiring an additional 758 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Zentalis Pharmaceuticals by 132.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,809 shares of the company’s stock worth $36,000 after acquiring an additional 1,030 shares during the period. Quest Partners LLC purchased a new position in Zentalis Pharmaceuticals in the fourth quarter worth $38,000. Finally, Point72 Hong Kong Ltd bought a new position in Zentalis Pharmaceuticals in the 1st quarter valued at $72,000.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on ZNTL shares. Wedbush lowered Zentalis Pharmaceuticals from an “outperform” rating to a “neutral” rating and lowered their target price for the stock from $38.00 to $12.00 in a research report on Wednesday, November 8th. Morgan Stanley lowered their price objective on shares of Zentalis Pharmaceuticals from $55.00 to $38.00 and set an “overweight” rating on the stock in a report on Tuesday, November 7th. SVB Leerink cut shares of Zentalis Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $15.00 price objective for the company. in a report on Tuesday, November 7th. Stifel Nicolaus lowered their target price on shares of Zentalis Pharmaceuticals from $44.00 to $36.00 and set a “buy” rating on the stock in a report on Tuesday, November 7th. Finally, HC Wainwright dropped their price target on shares of Zentalis Pharmaceuticals from $55.00 to $46.00 and set a “buy” rating on the stock in a research report on Tuesday, November 7th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Zentalis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $38.14.

Read Our Latest Report on ZNTL

Zentalis Pharmaceuticals Company Profile

(Get Free Report)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

Featured Stories

Insider Buying and Selling by Quarter for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.